MS4A1 and T-cell non-Hodgkin lymphoma: A review by Kakinoki et al. qualitatively found that CD20 staining intensity roughly correlated with the cancer’s response to therapy, with T cell lymphomas that had stronger CD20 expression appearing to enter remission more readily compared to others that displayed weak or variable CD20 expression [47].